Alcresta

IN THE PRESS

Genetown

Alcresta Therapeutics Announces Commercial Availability of Next-Generation RELiZORB® (iMMOBILIZED LIPASE) Cartridge

May 13, 2024

·

3 min read

Genetown

Alcresta Therapeutics Announces Publication of Cystic Fibrosis Foundation Position Paper Confirming Inline Enzyme Cartridges are Safe and Effective

July 25, 2023

·

2 min read

Drug Development

Alcresta Therapeutics Announces Preclinical Data Showing ALC-078 Cartridge Use in SBS Model Associated with Reduced Dependence on Parenteral Nutrition

March 16, 2023

·

5 min read

Business

Alcresta Therapeutics Announces Series of Commercial Milestone Achievements for RELiZORB®

April 1, 2022

·

2 min read

Business

Alcresta Therapeutics Announces Appointment of Chris Parrish as Chief Operations Officer

November 29, 2021

·

2 min read

Genetown

Alcresta Therapeutics Announces Medicare Local Coverage Determination that Confirms Coverage for RELiZORB®

September 7, 2021

·

2 min read

Pharm Country

Alcresta Therapeutics Announces Publication of Consensus Statement Supporting Access to RELiZORB®

June 25, 2019

·

3 min read

Pharm Country

Data from the ASSURE Study of Long-Term Use of RELiZORB® Published in Journal of Pediatric Gastroenterology and Nutrition

August 2, 2018

·

4 min read

Pharm Country

Alcresta Therapeutics Announces RELiZORB® iMMOBILIZED LIPASE CARTRIDGE has been Issued a Unique Q-Code (Q9994) by CMS

June 19, 2018

·

1 min read

Pharm Country

Alcresta Therapeutics Presented Results at the North American Cystic Fibrosis Conference from the ASSURE Study: An Evaluation of the Long-Term Use of RELiZORB

November 6, 2017

·

4 min read

AWARDS

JOBS